Form 4: J&J MedTech EVP Schmid Reports Share Transactions

Timothy Schmid, EVP and WW Chair of MedTech at Johnson & Johnson, disclosed a series of equity transactions including RSU and PSU vestings, option exercises, and corresponding share sales for tax and profit realization.

Summary

• Timothy Schmid, EVP, WW Chair, MedTech at Johnson & Johnson, reported multiple equity transactions.
• Transactions included the vesting of Restricted Share Units (RSUs) and Performance Share Units (PSUs), resulting in the acquisition of common stock.
• Shares were withheld for tax payments upon the vesting of RSUs and PSUs, totaling 8 shares (at $244.55), 1,816 shares (at $244.55), 15 shares (at $243.45), and 448 shares (at $243.45).
• Schmid exercised employee stock options, acquiring 13,625 shares at $115.67 and 8,998 shares at $129.51.
• Immediately following option exercises, Schmid sold 13,625 shares at a weighted average price of $244.20-$244.28 and 8,998 shares at $244.53.
• New derivative awards include 35,489 Employee Stock Options (Right to Buy) with an exercise price of $243.45 and 2,548 Restricted Share Units.
• Following these transactions, Schmid directly beneficially owns 26,769 shares of Common Stock.
• Indirect beneficial ownership includes 745 shares in a 401k and 46 shares in an ESOP as of January 31, 2026.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine executive compensation activities, including vesting, option exercises, and associated share sales, which are expected disclosures for a public company executive.

Positives

• The executive is receiving significant equity awards (RSUs, PSUs, stock options) as part of the company's Long-Term Incentive Plan, indicating continued alignment with shareholder interests.
• The exercise of stock options and subsequent sale of shares demonstrates the executive realizing value from previously granted compensation, which is a normal part of executive compensation.
• The transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned and orderly management of equity holdings.

Negatives

• The sales of shares, while common for tax purposes and profit realization from option exercises, represent a reduction in direct common stock holdings by the executive.

Future Outlook

The filing primarily details past and current equity transactions and does not provide explicit forward-looking statements or guidance regarding the company's future performance. However, the vesting schedules for new RSU and stock option awards indicate future equity compensation events for the executive.

Industry Context

StockSavvy.ai notes that executive equity transactions, particularly those involving the exercise of options and subsequent sales, are standard practices for managing compensation and personal finances. The use of a Rule 10b5-1(c) plan aligns with best practices for insider trading compliance, demonstrating a pre-planned approach to equity management rather than opportunistic trading. This activity is typical for executives in large, established pharmaceutical and medical device companies like Johnson & Johnson.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of equity compensation, including RSUs, PSUs, and stock options with multi-year vesting schedules, is consistent with common practices among large-cap pharmaceutical and medical technology companies such as Pfizer, Medtronic, and Abbott Laboratories.
• The exercise prices of the options ($115.67 and $129.51) compared to the sale prices (around $244) indicate significant appreciation in JNJ's stock price over the vesting periods, reflecting a successful long-term incentive program similar to those seen at peer companies where executive compensation is tied to long-term shareholder value creation.

Stakeholder Impact

• Shareholders: The transactions are routine and reflect the executive's participation in long-term incentive plans, aligning executive interests with shareholder value. The sales are for tax and profit realization, which is a normal part of executive compensation.
• Employees: The filing does not directly impact general employees, but it highlights the company's equity compensation structure for executives.

Next Steps

• Future vesting of Restricted Share Units (RSUs) awarded on February 15, 2024, in two more annual equal installments.
• Future vesting of Restricted Share Units (RSUs) awarded on February 15, 2025, in two more annual equal installments.
• Future vesting of Restricted Share Units (RSUs) awarded on February 15, 2026, in three annual equal installments.
• Future vesting of Employee Stock Options awarded on February 15, 2026, in three equal annual installments.

Key Dates

Recommendation

The filing details routine executive equity transactions, including the vesting of awards and the exercise of stock options followed by sales. These actions are part of standard executive compensation and personal financial management, often pre-planned under Rule 10b5-1. They do not provide new fundamental information about Johnson & Johnson's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than these specific insider disclosures.

Keywords

Johnson & Johnson, JNJ, Timothy Schmid, SEC Form 4, Insider Trading, Stock Options, RSU, PSU, Equity Compensation, MedTech, Executive Compensation, Share Sale, Beneficial Ownership